AddedRisk Factors
•Reputational Risks: Actions or failures by partners or investee companies could negatively impact our reputation or business relationships.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•Termination or Non-Performance: Collaborations or joint ventures may be terminated early or fail to deliver anticipated benefits, leaving us without expected products, technologies, or revenue streams.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
There can be no assurance that any strategic investment, collaboration, or joint venture will achieve its intended objectives or generate anticipated benefits within a reasonable timeframe, or at all. Failure to successfully manage these risks could materially and adversely affect our business and growth prospects.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
To mitigate these risks, we have implemented strategies to reduce tariff exposure and closely monitor trade policy developments. However, recent litigation challenging the legality of certain tariffs before the U.S. Supreme Court introduces additional uncertainty. If such tariffs are deemed unlawful, resulting policy reversals or retaliatory measures could create new risks and volatility in global trade, which may adversely affect our operations and financial results.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
• place us at a disadvantage compared to our competitors who have less debt; and
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
Following identification of these material weaknesses, and as part of our commitment to strengthen our internal control over financial reporting, we are implementing remedial actions under the oversight of the Audit Committee of our Board to address these deficiencies. Our remediation activities will include the following:
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our remediation activities include the following with respect to revenue recognition:
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
• Designing and implementing new internal controls to validate there is a complete listing of revenue contracts that have non-standard terms, which require incremental accounting analysis under ASC 606.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
• Designing and implementing new internal controls evaluating the accounting for contract amendments, including amendments accounted for as contract modifications.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
• Enhancing and expanding our existing revenue recognition control procedures and attributes when evaluating the accounting impact of non-standard contract terms and contract modifications.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
• Increased education for internal resources on accounting for contracts within the scope of ASC 606 and deploying enablers to facilitate documentation of accounting analyses and conclusions.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our remediation activities will include the following with respect to IT general controls:
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
• Reassessing the operating effectiveness of internal controls related to the program and data change management and user access processes; and
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our remediation activities will include the following with respect to certain business process-level controls:
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedRisk Factors
• Reassessing the operating effectiveness of these controls, including precision thresholds, timely execution, and documentation requirements for control owners;
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RewordedRisk Factors
In Europe, As currently enacted, the AI Act, which may now be amended as part of the EU’s Artificial Intelligence Act (“AI Act”) - which entered into force on August 1, 2024 and, with some exceptions, will begin to apply as of August 2, 2026 - Digital Omnibus imposes significant obligations on providers and deployers of high-risk artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We Though we continue to actively and selectively pursue patent protection and seek to expand our patent estate, particularly for our products currently in development, and protection, we cannot be sure guarantee that any patent applications that we will file in the future or that any currently pending applications will issue on a timely basis, if ever.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
These In addition, we face physical risks include risks to our manufacturing and supply chain from associated with climate change, including flooding, severe storms, wildfires, droughts or droughts, and extreme temperatures, all of which could disrupt manufacturing and supply chains, increase costs costs, and impair our ability to meet customer demands in a timely manner. demand.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are subject to data privacy and protection security laws and regulations in various jurisdictions that apply to the collection, transmission, storage storage, security and use of proprietary information and personally-identifying information, personal data, which among other things, imposes certain requirements relating to the privacy, security and transmission of certain individually identifiable information. impose significant compliance obligations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Specifically, Legislative and regulatory proposals in both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals abroad continue to change the seek changes to health care system in ways systems that could affect our ability to sell our products profitably.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including imposing special requirements in respect of the processing of health and other sensitive data, requiring that consent of individuals to whom the personal data relates is obtained in certain circumstances, requiring additional disclosures to individuals regarding data processing activities, requiring that safeguards are implemented to protect the security and confidentiality of personal data, limiting retention periods for personal data, creating mandatory data breach notification requirements in certain circumstances, and requiring that certain measures (including contractual requirements) are put in place when engaging third-party service providers.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Patents that may be granted to us in Relatedly, certain foreign countries patent applications may be subject to opposition proceedings brought by third parties or result in suits by us, parties, which may be costly and result in adverse consequences for us.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our acquisitions strategic investments, collaborations and joint ventures with and into business expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of such investments, collaborations and/or joint ventures with or into such businesses or technologies. technologies
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
As a result of Based on these unremediated material weaknesses, our the Company’s management concluded that our at December 31, 2025, the Company’s internal control over financial reporting was not effective as of December 31, 2024. effective.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In some cases, Though we are not currently involved in any ongoing litigation or other proceeding regarding intellectual property, litigation or other proceedings may be necessary to assert claims of infringement, infringement or misappropriation, to enforce patents issued to us or our licensors, to protect trade secrets, know-how or other intellectual property rights we own or to determine the scope and validity of the proprietary rights of third parties.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, if any of our current or future products compete with those of any of our largest customers, these customers may place fewer orders with us or cease placing orders with us, which would negatively affect our revenues and operating results.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
It is possible that stakeholders Stakeholders may not be satisfied with our ESG practices or the speed pace of their adoption, or that we may not sufficiently fail to communicate our ESG practices sufficiently to stakeholders. them effectively.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our Any future corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our any future restructuring efforts due to unforeseen difficulties, delays or unexpected costs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
A material cyber-attack or other security incident or compromise could cause interruptions in our operations and could result in a material disruption of our business operations, damage to our reputation or a loss of revenues.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Such litigation could result in adverse judgments, substantial costs to us us, and diversion of our resources.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On March 4, 2025, the Company completed its acquisition of 908 Devices Inc.’s (“908 Devices”) desktop portfolio of four devices for bioprocessing process analytical technology applications (“PAT Portfolio”). In connection with the transaction, Repligen also acquired facilities, employees, equipment and lease obligations for facilities in North Carolina and Braunschweig, Germany as well as certain working capital balances related to the PAT Portfolio. This transaction is referred to as the 908 Devices PAT Portfolio acquisition.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The addition of these desktop assets complements and strengthens Repligen’s differentiated PAT Portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
A change in the estimated timing or amount of demand for our products could result in additional provisions for excess inventory quantities on hand. In addition, significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Fair value of contingent consideration includes estimates and judgments made by management regarding the probability that future contingent payments will be made and the extent of payments to be earned in excess of defined minimum sales thresholds and achievement of defined milestones. To the extent that our estimates change in the future regarding the likelihood of achieving these targets, we may need to record material adjustments to our accrued contingent consideration. Such changes in the fair value of contingent consideration are recorded as contingent consideration in our consolidated statements of comprehensive income or loss.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, product revenue increased by $103.8 million, or 16.4% , compared to 2024. This growth is widespread across our portfolio of products and includes significant contributions from all our franchises. Geographically, product revenue increased 15.7% in North America, 16.0% in Europe and 19.3% in Asia Pacific and the rest of the world. Related to our acquisitions, products acquired from
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
908 Devices contributed $9.3 million in revenue during the year ended December 31, 2025. In addition, the year ended December 31, 2024 included $11.5 million of COVID-19 related sales.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, cost of goods sold decreased $7.8 million, or 2.2%, compared to 2024. The decrease in cost of goods sold is primarily due to lower costs related to scrap, excess and obsolete inventory and restructuring activities in 2025, compared to those incurred in 2024. Restructuring relates to activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. These decreases were partially offset by higher export duties, direct material and labor costs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, gross margin was 52.3%, compared to 43.3% in 2024. The increase in gross margin resulted from the decrease in cost of goods sold as described above.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
See Note 5, “Restructuring Activities and Other Inventory-Related Charges” in the notes to the consolidated financial statements, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K, for more detail.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On July 4, 2025, the United States enacted into law new tax legislation, the One Big Beautiful Bill Act (“OBBBA”), which contains several provisions modifying the corporate income tax code such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, updates to the international tax framework and the reinstatement of certain business-related provisions. The legislation has multiple effective dates, with provisions taking effect from 2025 through 2027. The changes effective in 2025 are included in our provision for income taxes for the year ended December 31, 2025 and were not material. We do not expect the OBBBA to have a material impact on our consolidated financial statements or results of operations in future periods.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
See Note 10, “Income Taxes” in the notes to the consolidated financial statements, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K for more detail.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Net (decrease) increase in cash and cash equivalents $ (191,334) $ 6,032 $ (197,366)
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. We do not assess whether a significant financing component exists if the period between when we perform our obligations under the contract and when the customer pays is one year or less. None of our contracts contained a significant financing component as of December 31, 2024.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. We determine standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
We recognize product revenue under the terms of each customer agreement upon transfer of control to the customer, which occurs at a point in time.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
Shipping and handling fees are recorded as a component of product revenue, with the associated costs recorded as a component of cost of goods sold in our consolidated statements of comprehensive income.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
A change in the estimated timing or amount of demand for our products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. In 2024, we recorded $36.0 million in inventory adjustments, which includes the impact of the Company discontinuing the sale of certain product SKUs and the impact of having proactively secured materials during the pandemic to meet accelerated demand during a challenging supply chain environment in the industry. Where demand has reduced, finished goods and raw materials, whose value exceeded the projected requirements to be used before reaching their expiration date, or in a reasonable time horizon, were written down to their realizable value. The Restructuring Plan described in Note 7, “Restructuring Activities and Other Inventory-Related Charges,” to our consolidated financial statements, also includes the closing of manufacturing facilities and excess production lines, which included inventory that could not be repurposed.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
We test goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying value. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, macroeconomic conditions, industry and market conditions, entity specific factors such as strategies and financial performance, a significant adverse change in legal factors and an adverse action or assessment by a regulator. Goodwill is tested for impairment as of October 1 of each year, or more frequently as warranted by events or changes in circumstances mentioned above. Accounting guidance also permits an optional qualitative assessment for goodwill to
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
determine whether it is more likely than not that the carrying value of a reporting unit exceeds its fair value. If, after this qualitative assessment, we determine that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then no further quantitative testing would be necessary. A quantitative assessment is performed if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent the reporting unit’s carrying value exceeds its fair value.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
We operate as one reporting unit. We performed a qualitative assessment for our reporting unit as of October 1, 2024, December 31, 2023 and December 31, 2022. Based on the assessment, we concluded that it was more likely than not that the estimated fair value of our reporting unit for 2024, 2023 and 2022 was higher than its carrying value for such years, and that the performance of the quantitative impairment test was not required. Therefore, no impairment was required for any of the periods presented.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
Prior to fiscal year 2024, testing of impairment on our goodwill occurred annually as of our measurement date of December 31st, pursuant to Company policy. Subsequent to the 2023 annual impairment test, which was completed on December 31, 2023, we voluntarily changed our annual impairment assessment date from December 31st to October 1st, the first day of our fourth quarter, beginning on October 1, 2024. The change is being made to better align the annual impairment assessment date with our annual planning and budgeting process as well as the long-term planning and forecasting process. We have determined that this voluntary change in accounting principle is preferable and will not impact our consolidated financial statements nor is it being done to accelerate, avoid or trigger an impairment charge. This change is not going to be applied retrospectively as it is impracticable to do so because retrospective application would require application of significant estimates and assumptions with the use of hindsight. Therefore, the change will be applied prospectively.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
We evaluated the Exchange Transaction and determined approximately $29.6 million of the $217.7 million principal of the exchanged 2019 Notes were accounted for as extinguishments of debt and approximately $188.1 million were accounted for as modification of debt. As a result, we recognized a $12.7 million loss on extinguishment of debt in our consolidated statements of comprehensive income for the year ended December 31, 2023. This included unamortized debt issuance costs related to the extinguished 2019 Notes. Under modification accounting, the carrying amount of the modified 2019 Notes was reduced by $2.8 million, with the offset going to additional paid-in capital, to account for the increase in fair value of the embedded conversion option in the modification. The increase in principal, along with the increased option value, totaling $82.1 million, is reflected as a debt discount and is a direct reduction from the carrying value of the debt on our consolidated balance sheets. This amount will be accreted as an adjustment to interest expense using the effective interest method and will accrete up to the full face value of the 2023 Notes of $600.0 million.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
Proceeds from the Subscription Transactions amounted to $276.1 million after debt issuance costs of $14.0 million. The exchange resulted in $6.2 million of the debt issuance costs related to the modified notes to be recorded to amortization of debt issuance costs in our 2023 consolidated statement of comprehensive income under the rules of modification accounting. The remaining debt issuance costs of $7.8 million as well as $0.7 million of unamortized costs carried over from the 2019 Notes at the exchange date, were capitalized within long-term debt (as a contra-liability) in our consolidated balance sheets and will be amortized as an adjustment to amortization of debt issuance costs over the five-year term of the 2023 Notes in our consolidated statement of comprehensive income. The carrying value of the 2023 Notes of $525.6 million is included in long-term debt on our consolidated balance sheets as of December 31, 2024.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RemovedMD&A
Prior to the close of business on the business day immediately preceding September 15, 2028, the 2023 Notes will be convertible at the option of the holders of 2023 Notes only upon the satisfaction of specified conditions and during certain periods into cash up to their principal amount, and into cash, shares of the Company's common stock or a combination of cash and the Company's common stock, at the Company's election, for the conversion value above the principal amount, if any. Thereafter until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2023 Notes will be convertible at the options of the holders of 2023 Notes at any time regardless of these conditions. The Company may redeem for cash, all or a portion of the 2023 Notes, at its option, on or after December 18, 2026 and prior to the 21st scheduled trading day immediately preceding the maturity date at a redemption price of 100% of the principal amount of the 2023 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date, if certain conditions are met in accordance to the indenture.
Read it in 10-K Mar 14, 2025 at sec.govopen_in_new
RewordedMD&A
Information pertaining to fiscal years 2024 and 2023 and 2022 was included in the Company’s Annual Report on Form 10-K/A (“Form 10-K/A”) 10-K for the year ended December 31, 2023, 2024, on pages 36 39 through 50 52 under Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which was filed with the Securities and Exchange Commission SEC on November 18, 2024 and Form 10-K for the year ended December 31, 2022, on pages 37 through 53 under Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which was filed with the Securities and Exchange Commission on February 22, 2023, respectively. March 14, 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
For 2024, 2025, our operating activities provided cash of $175.4 $117.4 million reflecting net loss income of $25.5 $48.9 million and non-cash charges totaling $140.0 $119.4 million primarily related to depreciation, intangible depreciation and amortization, stock-based compensation, right of use asset amortization, amortization of debt discount and issuance costs, contingent consideration fair value adjustments, net unrealized foreign exchange gains and deferred income taxes, stock-based compensation charges, loss on disposal of fixed assets, and right of use asset amortization. taxes.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our investing activities consumed $123.3 $298.5 million of cash in 2023, 2025, primarily due to $186.6 $200.3 million in cash (net of cash received) used for the 2023 acquisitions purchase of Metenova marketable securities and FlexBiosys, in $70.3 million, net of cash acquired, primarily used for the aggregate. acquisition of the 908 Devices PAT Portfolio.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
See Note 15, 13, “Convertible Senior Notes,” Notes” in the notes to our the consolidated financial statements statements, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this report Annual Report on Form 10-K for more information on this transaction. detail.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We believe The Company believes the estimated purchased customer relationships, developed technologies, trademark/tradename, patents, non-competition agreements trademark/tradename and in-process research and development ("R&D") amounts so determined other intangible assets identified in its acquisitions represent the fair value at the date of acquisition acquisition, and do not exceed the amount a third-party would pay for the such assets.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
For the Years Year Ended December 31, 2025 2024 vs 2023 2024 2023 $ Change % Change (Amounts in thousands, except for percentage data) thousands) Income tax provision (benefit) provision $ 13,489 $ (1,521) $ 21,111 $ (22,632) (107.2 $15,010 (986.9 Effective tax rate 21.6% 5.6% 37.2%
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Accounts These unfavorable changes in working capital were partially offset by increases in accounts payable and other accrued expenses provided $19.0 million liabilities of $6.0 million, due to the timing of in payments to vendors.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
These direct sales have represented 90.8% of our total product revenue during 2025 compared to 89.7% of our total product revenue during 2024 compared to 85.8% of our total product revenue in 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
For the Years Year Ended December 31, 2025 2024 2023 (Amounts in thousands) Filtration products $ 402,792 $ 372,963 $ 341,379 Chromatography products 153,176 122,810 126,629 Process analytics products 81,237 59,301 56,820 Proteins products 97,435 74,425 103,463 Other 3,320 4,679 3,688 Total product revenue $ 737,960 $ 634,178 $ 631,979
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We are subject to a territorial tax system under the Tax Cuts and Jobs Act enacted in December 2017, in which we are required to provide for tax on Global Intangible Low-Taxed Income (“GILTI”) earned by certain foreign subsidiaries.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The following discussion of the financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the related footnotes thereto. footnotes, included within Part IV, Item 15, “Exhibits and Financial Statement Schedules”, in this Annual Report on Form 10-K.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Since 2016, we have been increasingly We are continuously focused on selling our products directly to customers in the life sciences and pharmaceutical industry and to our contract manufacturers. industries, including CDMOs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new